USD
$0.00
(0.00%
)At Close (As of Sep 26, 2025)
$109.22M
Market Cap
-
P/E Ratio
-1.21
EPS
$3.95
52 Week High
$0.69
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $1.9M |
Total Revenue | $5.7M |
Cost Of Revenue | $3.8M |
Costof Goods And Services Sold | $3.8M |
Operating Income | -$81M |
Selling General And Administrative | $19M |
Research And Development | $67M |
Operating Expenses | $86M |
Investment Income Net | - |
Net Interest Income | $5.2M |
Interest Income | $5.2M |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $3.8M |
Income Before Tax | -$75M |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$75M |
Comprehensive Income Net Of Tax | - |
Ebit | -$81M |
Ebitda | -$77M |
Net Income | -$75M |
Field | Value (USD) |
---|---|
Gross Profit | $1.9M |
Total Revenue | $5.7M |
Cost Of Revenue | $3.8M |
Costof Goods And Services Sold | $3.8M |
Operating Income | -$81M |
Selling General And Administrative | $19M |
Research And Development | $67M |
Operating Expenses | $86M |
Investment Income Net | - |
Net Interest Income | $5.2M |
Interest Income | $5.2M |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $3.8M |
Income Before Tax | -$75M |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$75M |
Comprehensive Income Net Of Tax | - |
Ebit | -$81M |
Ebitda | -$77M |
Net Income | -$75M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Shattuck Labs, Inc. is a clinical-stage biotechnology company based in Austin, Texas, focused on advancing innovative therapies for cancer and autoimmune diseases. Leveraging its proprietary technology platforms, the company is dedicated to developing targeted treatments aimed at addressing significant unmet medical needs. With a strong commitment to research and development, Shattuck Labs is positioned to make impactful contributions to the biopharmaceutical industry, aiming to improve patient outcomes through its next-generation therapeutics.